Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses
Launched by COOPERVISION, INC. · Dec 16, 2022
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
The aim of this non-dispensing fitting study was to evaluate the short-term clinical performance of two soft spherical contact lenses after 15 minutes of daily wear each.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Is at least 18 years of age and has full legal capacity to volunteer.
- • Has read and signed an information consent letter.
- • Self-reports having a full eye examination in the previous two years.
- • Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week.
- • Is willing and able to follow instructions and maintain the appointment schedule.
- • Habitual soft contact lens wearers who currently wear sphere contact lenses, or use spectacles for all distances vision correction, for the past 3 months minimum.
- • Has refractive astigmatism no higher than -0.75DC.
- • Can be fit and achieve binocular distance vision of at least 20/30 Snellen (or +0.20 logMAR) which participants also deem to be 'acceptable', with the available study lens parameters (powers +8.00 to -12.00DS)
- Exclusion Criteria:
- • Is participating in any concurrent clinical or research study.
- • Has any known active ocular disease and/or infection that contraindicates contact lens wear.
- • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable.
- • Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable.
- • Has known sensitivity to the diagnostic sodium fluorescein used in the study.
- • Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment.
- • Has undergone refractive error surgery or intraocular surgery.
About Coopervision, Inc.
CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
Juan G Carracedo Rodríguez, OD,MSc,PhD
Principal Investigator
University Complutense of Madrid
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials